Critical evaluation of the efficacy and tolerability of azilsartan

Vascular Health and Risk Management, 05/16/2012

The aim of this paper is to describe the efficacy and safety profile of this new compound, reviewing available data obtained from both pre–clinical and clinical studies.

  • Appropriate control of blood pressure (BP) in hypertensive patients still represents the major therapeutic goal in the treatment of hypertension.
  • Despite the growing attention and wide range of antihypertensive agents available in the clinical scenario, the target of BP below the advised thresholds of 140/90 mmHg is, unfortunately, often unreached.
  • For this reason, the search for new antihypertensive agents is still ongoing.
  • Azilsartan medoxomil, a new angiotensin receptor blocker that has been recently introduced in the clinical arena, represents the eighth angiotensin receptor blocker currently available for BP control.

Print Article Summary